US 12,226,478 B2
Method of treating, reducing, or alleviating a medical condition in a patient
Gholam A. Peyman, Sun City, AZ (US)
Filed by Gholam A. Peyman, Sun City, AZ (US)
Filed on Jun. 29, 2023, as Appl. No. 18/216,531.
Application 18/216,531 is a continuation in part of application No. 17/699,055, filed on Mar. 18, 2022, granted, now 11,707,518.
Application 17/699,055 is a continuation in part of application No. 17/180,784, filed on Feb. 20, 2021, granted, now 11,648,261, issued on May 16, 2023.
Application 17/180,784 is a continuation in part of application No. 16/861,128, filed on Apr. 28, 2020, granted, now 10,925,889, issued on Feb. 23, 2021.
Claims priority of provisional application 63/306,042, filed on Feb. 2, 2022.
Claims priority of provisional application 63/239,927, filed on Sep. 1, 2021.
Claims priority of provisional application 63/221,852, filed on Jul. 14, 2021.
Claims priority of provisional application 63/209,331, filed on Jun. 10, 2021.
Claims priority of provisional application 63/181,948, filed on Apr. 29, 2021.
Claims priority of provisional application 63/177,916, filed on Apr. 21, 2021.
Claims priority of provisional application 63/162,986, filed on Mar. 18, 2021.
Claims priority of provisional application 63/131,761, filed on Dec. 29, 2020.
Claims priority of provisional application 63/106,319, filed on Oct. 27, 2020.
Claims priority of provisional application 63/077,677, filed on Sep. 13, 2020.
Claims priority of provisional application 63/055,770, filed on Jul. 23, 2020.
Claims priority of provisional application 63/039,959, filed on Jun. 16, 2020.
Claims priority of provisional application 63/016,258, filed on Apr. 27, 2020.
Claims priority of provisional application 62/839,738, filed on Apr. 28, 2019.
Prior Publication US 2023/0338520 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 31/132 (2006.01); A61K 31/155 (2006.01); A61K 31/4045 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/12 (2006.01); A61K 45/06 (2006.01); A61M 1/14 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 31/132 (2013.01); A61K 31/155 (2013.01); A61K 31/4045 (2013.01); A61K 39/0002 (2013.01); A61K 39/0011 (2013.01); A61K 39/02 (2013.01); A61K 39/12 (2013.01); A61K 45/06 (2013.01); A61M 1/14 (2013.01); A61K 2039/55511 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A method for producing an immunogenic composition, the method comprising:
growing viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium;
killing the viruses, bacteria, fungi, parasites, or tumor cells in the cell culture or other appropriate medium with one or more medications that damage the RNA and/or the DNA of the viruses, bacteria, fungi, parasites, or tumor cells, wherein the viruses, bacteria, fungi, parasites, or tumor cells remain in contact with the one or more medications for a period of time that is sufficient for the one or more medications to penetrate the viruses, bacteria, fungi, parasites, or tumor cells and attach to RNA or DNA of the viruses, bacteria, fungi, parasites, or tumor cells and prevent multiplication of the viruses, bacteria, fungi, parasites, or tumor cells;
separating the dead viruses, bacteria, fungi, parasites, or tumor cells from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge;
depending on the type of organism, adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form an immunogenic composition; and
administering the immunogenic composition and an adjuvant to a patient in need thereof.